StemRIM Inc. (JP:4599) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
StemRIM Inc. has commenced a Phase 2 clinical trial for its regenerative medicine product, Redasemtide, targeting ischemic cardiomyopathy at Osaka University Hospital. This trial aims to evaluate the efficacy and safety of the treatment in patients who have undergone coronary artery bypass grafting, with results expected to be monitored 52 weeks post-treatment. Despite this development, it is not anticipated to impact the company’s financial results for the current fiscal year.
For further insights into JP:4599 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Will Shari Redstone’s Relationship With Trump Save Paramount (NASDAQ:PARA) Merger?
- Ford (NYSE:F) Offers Free Cars to Trump Inauguration
- Rest Easy, Intel (NASDAQ:INTC): Broadcom Is Not Coming For You
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
